Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Where do you start when developing a new medicine?
Initiative between GSK, EMBL-EBI and Sanger Institute is using ‘big data’ & genome sequencing improving chances for discovering new drugs.
-
GSK receives European authorisation for once-weekly type 2 diabetes treatment, Eperzan® (albiglutide)
GSK announced that the EC has granted marketing authorisation for its once-weekly diabetes treatment, Eperzan® (albiglutide).
-
Regulatory update: combined use of Mekinist™ (trametinib) and Tafinlar® (dabrafenib) in Europe
GSK today announced that it has withdrawn its MAA to EMA for the use of Mekinist (trametinib) in combination with Tafinlar (dabrafenib).
-
GSK publishes historical quarterly restated financial information
GSK will adopt a revised presentation for the analysis of its Pharmaceuticals and Vaccines turnover by segment, product and therapeutic area
-
Investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoints in MAGRIT, a phase III non-small cell lung cancer clinical trial
GSK announced that the MAGRITi phase III trial of MAGE-A3 cancer immunotherapeuticii in NSCLC patients did not meet its primary endpoint.
-
GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS® in patients with COPD
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from three phase III studies.
-
Patient recruitment completes in landmark RELVAR®/ BREO® ELLIPTA® Study to Understand Mortality and MorbidITy (SUMMIT) in COPD
GSK & THRX announced that recruitment of patients into the study known as SUMMIT, has completed enrolment.
-
GSK announces positive results from phase III studies for mepolizumab in severe eosinophilic asthma
GSK announced that, pivotal phase III study of mepolizumab, an investigational IL-5 antagonist monoclonal antibody, met its primary endpoint
-
GSK increases stake in Indian Pharmaceuticals subsidiary to 75 per cent after Open Offer
GSK announced that, it has successfully increased its stake in its publicly-listed pharmaceuticals subsidiary in India.
-
GSK announces submission to U.S. regulatory authorities for Promacta™ (eltrombopag) for severe aplastic anaemia
GSK announced the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA for Promacta™ (eltrombopag).
-
GSK kicks off 2014 Discovery Fast Track Challenge for academic drug hunters in Europe, Canada and USA
GSK is inviting academic scientists to enter their most innovative drug research proposals into its 2014 Discovery Fast Track Challenge.
-
GSK receives positive CHMP opinion for Incruse® (umeclidinium) for the treatment of COPD
GSK announced that EMA's CHMP is recommending marketing authorisation for umeclidinium, treatment to relieve symptoms in patients with COPD.
-
Anoro® (umeclidinium / vilanterol) receives positive opinion from the CHMP in Europe for the treatment of COPD
GSK & THRX announced that CHMP of EMA has issued a positive opinion recommending marketing authorisation for UMEC/VI ,brand name Anoro®
-
GSK announces start of Phase lll study for mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis
GSK today announced the start of a Phase III study to evaluate the efficacy and safety of mepolizumab, an investigational IL-5 antagonist.
-
Results announcement for fourth quarter 2013
GSK announces core EPS of 112.2p and dividend of 78p.
-
GSK gains FDA Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag) for severe aplastic anaemia
GSK announced that the U.S. FDA has granted Breakthrough Therapy designation for Promacta®/Revolade® (eltrombopag).
-
GSK receives positive opinion from the CHMP in Europe for once-weekly EperzanTM (albiglutide) for the treatment of type 2 diabetes
GlaxoSmithKline plc today announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion albiglutide
-
GSK announces headline results for Phase III study of the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) in metastatic melanoma
GSK announced that a Phase III study of the combination of Tafinlar® (dabrafenib) and Mekinist® (trametinib) met its primary endpoint of PFS
-
ViiV Healthcare’s new HIV medicine TivicayTM (dolutegravir) is approved in Europe
ViiV Healthcare today announced that the European Commission has approved TivicayTM (dolutegravir).
-
Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation
GSK announced today that the U.S. FDA has granted Breakthrough Therapy designation for Tafinlar® (dabrafenib).